Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

December 14, 2020December 14, 2020

Takhzyro Approved in China for Routine Prevention of HAE Attacks

News

Takeda’s Takhzyro (lanadelumab) has been approved in China for the routine prevention of hereditary angioedema (HAE) attacks in patients ages 12 and older, the company announced. It now becomes ... Read more

December 7, 2020December 7, 2020

FDA Approves Orladeyo, 1st Oral Treatment to Prevent HAE Attacks

News

The U.S. Food and Drug Administration has approved Orladeyo (berotralstat) as an oral treatment to prevent swelling attacks in people with hereditary angioedema (HAE), ages 12 and older. This ... Read more

September 21, 2020September 21, 2020

Enrollment Completed in Phase 2 Trial of Oral On-demand HAE Therapy KVD900

News

The Phase 2 clinical trial testing KalVista Pharmaceuticals‘ oral investigational therapy KVD900 as an on-demand treatment for hereditary angioedema (HAE) attacks has completed enrollment, the company announced. Results from the trial are expected by year’s ... Read more

May 13, 2020May 13, 2020

Costs Unsustainable for New Angioedema Preventive Therapies in US, Real-world Data Show

News

Costs are unsustainable for preventive treatment of hereditary angioedema (HAE) attacks with approved therapies Takhzyro or Haegarda, according to an analysis of six-month real-world data performed by the pharmacy benefit manager ... Read more

March 9, 2020March 9, 2020

Pediatric Rare Disease Therapies Increase, But Most Repurposed, Study Finds

News

The number of treatments for children with rare diseases has grown over the past decade, according to a new study. However, despite the increase, nearly 7,000 rare diseases are still ... Read more

February 25, 2020April 8, 2020

FDA Agrees to Review Berotralstat as Preventive Treatment for HAE Attacks

News

The U.S. Food and Drug Administration (FDA) agreed to review BioCryst Pharmaceuticals‘ application requesting approval of oral berotralstat as a once-daily treatment to prevent swelling attacks in people with ... Read more

February 11, 2020November 24, 2020

Preventive Therapy for HAE Attacks, Haegarda, Now Available in Quebec

News

Haegarda, a C1-INH replacement medication by CSL Behring, is now available in the Canadian province of Quebec for the preventive treatment of swelling attacks in adults and adolescents with ... Read more

February 4, 2020February 26, 2020

BioCryst Seeks Berotralstat Approval in Japan for Prevention of HAE Attacks

News

BioCryst Pharmaceuticals has submitted an application to the Japanese regulatory authority asking that oral berotralstat (BCX7353) be approved for the prevention of swelling attacks in people with hereditary angioedema ... Read more

January 30, 2020February 14, 2020

EMA Approves New Production Facility for Ruconest, Pharming’s Treatment for Acute HAE Attacks

News

The European Medicines Agency (EMA) has approved a type II variation for a new facility to produce Ruconest (conestat alfa), Pharming’s lead therapy for acute attacks in hereditary angioedema (HAE). ... Read more

January 13, 2020February 6, 2020

Update Coming on Phase 2 Trial of KalVista’s Oral HAE Therapy KVD900

News

Results of the Phase 2 clinical trial testing KalVista Pharmaceuticals‘ oral investigational therapy KVD900 as an on-demand treatment for hereditary angioedema (HAE) attacks will be announced by August. The ... Read more